Zobrazeno 1 - 10
of 31
pro vyhledávání: '"I. Alex Bowman"'
Autor:
Blaine Brower, Asia McCoy, Hiba Ahmad, Cheryl Eitman, I. Alex Bowman, Jennifer Rembisz, Matthew I. Milowsky
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Cisplatin-based chemotherapy has been the standard of care for patients with locally advanced or metastatic urothelial cancer (la/mUC). Enfortumab vedotin, an antibody-drug conjugate directed to Nectin-4, and pembrolizumab, an immune checkpoint inhib
Externí odkaz:
https://doaj.org/article/2aaa79c7a07e4d158c2f0a6869afa8c1
Autor:
Xiankai Sun, James Brugarolas, Guiyang Hao, Christina Stevens, I. Alex Bowman, Nirmish Singla, Vanina T. Tcheuyap, Alana Christie, Payal Kapur, Kien Nham, Bing Guan, Layton Woolford, Roy Elias, Aditi Mulgaonkar
Supplementary Table from ImmunoPET Imaging with 89Zr-Labeled Atezolizumab Enables In Vivo Evaluation of PD-L1 in Tumorgraft Models of Renal Cell Carcinoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::702b5730fdf898803eaa09b5ebbc6071
https://doi.org/10.1158/1078-0432.22489257.v1
https://doi.org/10.1158/1078-0432.22489257.v1
Autor:
Xiankai Sun, James Brugarolas, Guiyang Hao, Christina Stevens, I. Alex Bowman, Nirmish Singla, Vanina T. Tcheuyap, Alana Christie, Payal Kapur, Kien Nham, Bing Guan, Layton Woolford, Roy Elias, Aditi Mulgaonkar
Purpose:Immune checkpoint inhibitors (ICI) targeting the programmed cell death protein 1 and its ligand (PD-1/PD-L1) have transformed the treatment paradigm for metastatic renal cell carcinoma (RCC). However, response rates to ICIs as single agents o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98b07b3d292a34ae6f6fc9ab155467fd
https://doi.org/10.1158/1078-0432.c.6532917
https://doi.org/10.1158/1078-0432.c.6532917
Autor:
Xiankai Sun, James Brugarolas, Guiyang Hao, Christina Stevens, I. Alex Bowman, Nirmish Singla, Vanina T. Tcheuyap, Alana Christie, Payal Kapur, Kien Nham, Bing Guan, Layton Woolford, Roy Elias, Aditi Mulgaonkar
Supplementary Figure from ImmunoPET Imaging with 89Zr-Labeled Atezolizumab Enables In Vivo Evaluation of PD-L1 in Tumorgraft Models of Renal Cell Carcinoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37118b799a1cfafe59d06c481fac6415
https://doi.org/10.1158/1078-0432.22489272.v1
https://doi.org/10.1158/1078-0432.22489272.v1
Autor:
Aditi Mulgaonkar, Roy Elias, Layton Woolford, Bing Guan, Kien Nham, Payal Kapur, Alana Christie, Vanina T. Tcheuyap, Nirmish Singla, I. Alex Bowman, Christina Stevens, Guiyang Hao, James Brugarolas, Xiankai Sun
Publikováno v:
Clin Cancer Res
Purpose: Immune checkpoint inhibitors (ICI) targeting the programmed cell death protein 1 and its ligand (PD-1/PD-L1) have transformed the treatment paradigm for metastatic renal cell carcinoma (RCC). However, response rates to ICIs as single agents
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b5bbf7f34210ae9cf5f7f4317daa594
https://europepmc.org/articles/PMC9669181/
https://europepmc.org/articles/PMC9669181/
Autor:
Yair Lotan, Aditya Bagrodia, Xiaosong Meng, Nirmish Singla, Arthur I. Sagalowsky, Rashed Ghandour, I. Alex Bowman, Kevin D. Courtney, Ahmet M. Aydin, Nathan Chertack, Joseph A. Moore, Vitaly Margulis, Ryan Hutchinson, Yuval Freifeld, Solomon L. Woldu, Waddah Arafat
Publikováno v:
Cancer. 126:4362-4370
BACKGROUND The objective of this study was to determine whether standardized treatment of germ cell tumors (GCTs) could overcome sociodemographic factors limiting patient care. METHODS The records of all patients undergoing primary treatment for GCTs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::91e2c240abba5001b5d0053e29dbbe07
https://doi.org/10.1002/cncr.33076
https://doi.org/10.1002/cncr.33076
Autor:
Oscar Reig Torras, Akhilesh Mishra, Alana Christie, Tiffani McKenzie, Oreoluwa Onabolu, Nirmish Singla, Elizabeth R. Plimack, Cristina Suárez, Moshe C. Ornstein, R. Katherine Alpaugh, Roy Elias, I. Alex Bowman, Renee M. McKay, Christopher Przybycin, Payal Kapur, James Brugarolas, Brian Rini
Publikováno v:
Eur Urol
Active surveillance (AS) may be used in the management of metastatic renal cell carcinoma (mRCC), but consensus regarding its application is lacking. We report an exploratory analysis of prospectively collected data and specimens prespecified in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80b14daf40af3336912a7b066038deca
https://europepmc.org/articles/PMC9886196/
https://europepmc.org/articles/PMC9886196/
Autor:
Hima Anbunathan, Anne M. Bowcock, Yu Zhi Zhang, William O.C.M. Cookson, Miriam F. Moffatt, Tatyana Chernova, S. Gennatas, Anne E. Willis, Mark Lathrop, I. Alex Bowman, Eric Lim, A. Mandal, Marion MacFarlane, Anthony Newman Taylor, Sanjay Popat, Tim Benepal, A. Nastase, Matthew S. Edwards, Deborah J. Morris-Rosendahl, Robert C. Rintoul, Andrew G. Nicholson, Xiao-Ming Sun, Shir Kiong Lu
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-15 (2021)
Scientific Reports
Scientific Reports
Funder: Libor Fund grant from the UK Department of Health, by the British Lung Foundation and by the Asmarley Foundation
Funder: UK Medical Research Council
Pleural mesothelioma is an aggressive malignancy with limited effective therapies.
Funder: UK Medical Research Council
Pleural mesothelioma is an aggressive malignancy with limited effective therapies.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61d8c8d6242ca7614d7b4d3e2e4d965d
ROS1 Gene Rearrangements Are Associated With an Elevated Risk of Peridiagnosis Thromboembolic Events
Autor:
I. Alex Bowman, Robert C. Doebele, Shuo Yang, Rao Mushtaq, Siera Newkirk, Caicun Zhou, Dexiang Gao, Dara L. Aisner, Robert T. Jones, Terry L. Ng, Shengxiang Ren, Qian Liu, Joshua Bauml, Tejas Patil, Flora Yan, Stephen V. Liu, Anastasios Dimou, Megan M. Tu, Xuefei Li, Derek E. Smith, D. Ross Camidge
Publikováno v:
Journal of Thoracic Oncology. 14:596-605
Introduction This study aims to determine whether advanced ROS1 gene-rearranged NSCLC (ROS1+ NSCLC) has a higher than expected thromboembolic event (TEE) rate. Methods Venous and arterial TEEs within ±365 days of diagnosis of ROS1+, ALK+, EGFR+, or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21009aa7f43fa683a7318490c4f0352e
https://doi.org/10.1016/j.jtho.2018.12.001
https://doi.org/10.1016/j.jtho.2018.12.001
Autor:
Wanling Xie, Sumanta K. Pal, Daniel M. Geynisman, Elizabeth R. Plimack, Nieves Martinez Chanza, Jarred Burkart, Yousef Zakharia, Sumit A. Shah, Hannah Dzimitrowicz, Saby George, Mehmet Asim Bilen, Naomi B. Haas, Russell K. Pachynski, Walter M. Stadler, Dominick Bossé, I. Alex Bowman, Abhishek Tripathi, Lauren C. Harshman, Toni K. Choueiri, Nicholas J. Vogelzang, Sandy Srinivas, Andrew W. Hahn, Rana R. McKay, Anthony Mega, Benoit Beuselinck, Jo Ann Hsu, Vivek Narayan, Ulka N. Vaishampayan, Rohit Jain, Michael R. Harrison, Daniel Y.C. Heng, Neeraj Agarwal, Archana Balakrishnan, Benedito A. Carneiro, Amir Mortazavi, Hans J. Hammers, Elaine T. Lam, Tracy L. Rose
Publikováno v:
The Lancet Oncology. 20:581-590
Summary Background Cabozantinib is approved for patients with metastatic renal cell carcinoma on the basis of studies done in clear-cell histology. The activity of cabozantinib in patients with non-clear-cell renal cell carcinoma is poorly characteri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::20401f4babe8d94ec38c64545be9c490
https://doi.org/10.1016/s1470-2045(18)30907-0
https://doi.org/10.1016/s1470-2045(18)30907-0